Table of Content

1 Human Granulocyte Colony-stimulating Factor Market Overview
1.1 Product Overview and Scope of Human Granulocyte Colony-stimulating Factor
1.2 Human Granulocyte Colony-stimulating Factor Segment by Type
1.2.1 Global Human Granulocyte Colony-stimulating Factor Market Value Comparison by Type (2023-2033)
1.2.2 300μg/Dose
1.2.3 150μg/Dose
1.2.4 75μg/Dose
1.2.5 Others
1.3 Human Granulocyte Colony-stimulating Factor Segment by Application
1.3.1 Global Human Granulocyte Colony-stimulating Factor Market Value by Application: (2023-2033)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Human Granulocyte Colony-stimulating Factor Market Size Estimates and Forecasts
1.4.1 Global Human Granulocyte Colony-stimulating Factor Revenue 2018-2033
1.4.2 Global Human Granulocyte Colony-stimulating Factor Sales 2018-2033
1.4.3 Global Human Granulocyte Colony-stimulating Factor Market Average Price (2018-2033)
1.5 Assumptions and Limitations
2 Human Granulocyte Colony-stimulating Factor Market Competition by Manufacturers
2.1 Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Manufacturers (2018-2023)
2.2 Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Human Granulocyte Colony-stimulating Factor Average Price by Manufacturers (2018-2023)
2.4 Global Human Granulocyte Colony-stimulating Factor Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Product Type & Application
2.7 Human Granulocyte Colony-stimulating Factor Market Competitive Situation and Trends
2.7.1 Human Granulocyte Colony-stimulating Factor Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Granulocyte Colony-stimulating Factor Players Market Share by Revenue
2.7.3 Global Human Granulocyte Colony-stimulating Factor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Granulocyte Colony-stimulating Factor Retrospective Market Scenario by Region
3.1 Global Human Granulocyte Colony-stimulating Factor Market Size by Region: 2018 Versus 2022 Versus 2033
3.2 Global Human Granulocyte Colony-stimulating Factor Global Human Granulocyte Colony-stimulating Factor Sales by Region: 2018-2033
3.2.1 Global Human Granulocyte Colony-stimulating Factor Sales by Region: 2018-2023
3.2.2 Global Human Granulocyte Colony-stimulating Factor Sales by Region: 2024-2033
3.3 Global Human Granulocyte Colony-stimulating Factor Global Human Granulocyte Colony-stimulating Factor Revenue by Region: 2018-2033
3.3.1 Global Human Granulocyte Colony-stimulating Factor Revenue by Region: 2018-2023
3.3.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Region: 2024-2033
3.4 North America Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
3.4.1 North America Human Granulocyte Colony-stimulating Factor Market Size by Country: 2018 VS 2022 VS 2033
3.4.2 North America Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2033)
3.4.3 North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2018-2033)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
3.5.1 Europe Human Granulocyte Colony-stimulating Factor Market Size by Country: 2018 VS 2022 VS 2033
3.5.2 Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2033)
3.5.3 Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2018-2033)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
3.6.1 Asia Pacific Human Granulocyte Colony-stimulating Factor Market Size by Country: 2018 VS 2022 VS 2033
3.6.2 Asia Pacific Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2033)
3.6.3 Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Country (2018-2033)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
3.7.1 Latin America Human Granulocyte Colony-stimulating Factor Market Size by Country: 2018 VS 2022 VS 2033
3.7.2 Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2033)
3.7.3 Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country (2018-2033)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Granulocyte Colony-stimulating Factor Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Granulocyte Colony-stimulating Factor Market Size by Country: 2018 VS 2022 VS 2033
3.8.2 Middle East and Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2033)
3.8.3 Middle East and Africa Human Granulocyte Colony-stimulating Factor Revenue by Country (2018-2033)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2033)
4.1.1 Global Human Granulocyte Colony-stimulating Factor Sales by Type (2018-2023)
4.1.2 Global Human Granulocyte Colony-stimulating Factor Sales by Type (2024-2033)
4.1.3 Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2018-2033)
4.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2018-2033)
4.2.1 Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2018-2023)
4.2.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Type (2024-2033)
4.2.3 Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Type (2018-2033)
4.3 Global Human Granulocyte Colony-stimulating Factor Price by Type (2018-2033)
5 Segment by Application
5.1 Global Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2033)
5.1.1 Global Human Granulocyte Colony-stimulating Factor Sales by Application (2018-2023)
5.1.2 Global Human Granulocyte Colony-stimulating Factor Sales by Application (2024-2033)
5.1.3 Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2018-2033)
5.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2018-2033)
5.2.1 Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2018-2023)
5.2.2 Global Human Granulocyte Colony-stimulating Factor Revenue by Application (2024-2033)
5.2.3 Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Application (2018-2033)
5.3 Global Human Granulocyte Colony-stimulating Factor Price by Application (2018-2033)
6 Key Companies Profiled
6.1 Chugai Pharmaceutical
6.1.1 Chugai Pharmaceutical Corporation Information
6.1.2 Chugai Pharmaceutical Description and Business Overview
6.1.3 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.1.5 Chugai Pharmaceutical Recent Developments/Updates
6.2 Kyowa Hakko Kirin
6.2.1 Kyowa Hakko Kirin Corporation Information
6.2.2 Kyowa Hakko Kirin Description and Business Overview
6.2.3 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product Portfolio
6.2.5 Kyowa Hakko Kirin Recent Developments/Updates
6.3 Sanway
6.3.1 Sanway Corporation Information
6.3.2 Sanway Description and Business Overview
6.3.3 Sanway Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanway Human Granulocyte Colony-stimulating Factor Product Portfolio
6.3.5 Sanway Recent Developments/Updates
6.4 GenSci
6.4.1 GenSci Corporation Information
6.4.2 GenSci Description and Business Overview
6.4.3 GenSci Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GenSci Human Granulocyte Colony-stimulating Factor Product Portfolio
6.4.5 GenSci Recent Developments/Updates
6.5 SL PHARM
6.5.1 SL PHARM Corporation Information
6.5.2 SL PHARM Description and Business Overview
6.5.3 SL PHARM Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.5.4 SL PHARM Human Granulocyte Colony-stimulating Factor Product Portfolio
6.5.5 SL PHARM Recent Developments/Updates
6.6 Kexing Bioproducts
6.6.1 Kexing Bioproducts Corporation Information
6.6.2 Kexing Bioproducts Description and Business Overview
6.6.3 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product Portfolio
6.6.5 Kexing Bioproducts Recent Developments/Updates
6.7 Qilu Pharmaceutical
6.6.1 Qilu Pharmaceutical Corporation Information
6.6.2 Qilu Pharmaceutical Description and Business Overview
6.6.3 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.7.5 Qilu Pharmaceutical Recent Developments/Updates
6.8 CSPC
6.8.1 CSPC Corporation Information
6.8.2 CSPC Description and Business Overview
6.8.3 CSPC Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.8.4 CSPC Human Granulocyte Colony-stimulating Factor Product Portfolio
6.8.5 CSPC Recent Developments/Updates
6.9 Wuzhong Pharmaceutical
6.9.1 Wuzhong Pharmaceutical Corporation Information
6.9.2 Wuzhong Pharmaceutical Description and Business Overview
6.9.3 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.9.5 Wuzhong Pharmaceutical Recent Developments/Updates
6.10 Quangang Pharmaceutical
6.10.1 Quangang Pharmaceutical Corporation Information
6.10.2 Quangang Pharmaceutical Description and Business Overview
6.10.3 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.10.5 Quangang Pharmaceutical Recent Developments/Updates
6.11 Huabei Pharmaceutical
6.11.1 Huabei Pharmaceutical Corporation Information
6.11.2 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Description and Business Overview
6.11.3 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.11.5 Huabei Pharmaceutical Recent Developments/Updates
6.12 Harbin Pharmaceutical
6.12.1 Harbin Pharmaceutical Corporation Information
6.12.2 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Description and Business Overview
6.12.3 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.12.5 Harbin Pharmaceutical Recent Developments/Updates
6.13 Amoytop Biotech
6.13.1 Amoytop Biotech Corporation Information
6.13.2 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Description and Business Overview
6.13.3 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product Portfolio
6.13.5 Amoytop Biotech Recent Developments/Updates
6.14 Jiuyuan Gene Engineering
6.14.1 Jiuyuan Gene Engineering Corporation Information
6.14.2 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Description and Business Overview
6.14.3 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product Portfolio
6.14.5 Jiuyuan Gene Engineering Recent Developments/Updates
6.15 Four Rings Biopharmaceutical
6.15.1 Four Rings Biopharmaceutical Corporation Information
6.15.2 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Description and Business Overview
6.15.3 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product Portfolio
6.15.5 Four Rings Biopharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Granulocyte Colony-stimulating Factor Industry Chain Analysis
7.2 Human Granulocyte Colony-stimulating Factor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Granulocyte Colony-stimulating Factor Production Mode & Process
7.4 Human Granulocyte Colony-stimulating Factor Sales and Marketing
7.4.1 Human Granulocyte Colony-stimulating Factor Sales Channels
7.4.2 Human Granulocyte Colony-stimulating Factor Distributors
7.5 Human Granulocyte Colony-stimulating Factor Customers
8 Human Granulocyte Colony-stimulating Factor Market Dynamics
8.1 Human Granulocyte Colony-stimulating Factor Industry Trends
8.2 Human Granulocyte Colony-stimulating Factor Market Drivers
8.3 Human Granulocyte Colony-stimulating Factor Market Challenges
8.4 Human Granulocyte Colony-stimulating Factor Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Human Granulocyte Colony-stimulating Factor Market Value Comparison by Type (2023-2033) & (US$ Million)
Table 2. Global Human Granulocyte Colony-stimulating Factor Market Value Comparison by Application (2023-2033) & (US$ Million)
Table 3. Global Human Granulocyte Colony-stimulating Factor Market Competitive Situation by Manufacturers in 2022
Table 4. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) of Key Manufacturers (2018-2023)
Table 5. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Human Granulocyte Colony-stimulating Factor Average Price (USD/Dose) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Human Granulocyte Colony-stimulating Factor, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Product Type & Application
Table 12. Global Key Manufacturers of Human Granulocyte Colony-stimulating Factor, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Human Granulocyte Colony-stimulating Factor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Granulocyte Colony-stimulating Factor as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Human Granulocyte Colony-stimulating Factor Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 17. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2018-2023) & (K Dose)
Table 18. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2018-2023)
Table 19. Global Human Granulocyte Colony-stimulating Factor Sales by Region (2024-2033) & (K Dose)
Table 20. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2024-2033)
Table 21. Global Human Granulocyte Colony-stimulating Factor Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2018-2023)
Table 23. Global Human Granulocyte Colony-stimulating Factor Revenue by Region (2024-2033) & (US$ Million)
Table 24. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2024-2033)
Table 25. North America Human Granulocyte Colony-stimulating Factor Revenue by Country: 2018 VS 2022 VS 2033 (US$ Million)
Table 26. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (K Dose)
Table 27. North America Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2033) & (K Dose)
Table 28. North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Human Granulocyte Colony-stimulating Factor Revenue by Country (2024-2033) & (US$ Million)
Table 30. Europe Human Granulocyte Colony-stimulating Factor Revenue by Country: 2018 VS 2022 VS 2033 (US$ Million)
Table 31. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (K Dose)
Table 32. Europe Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2033) & (K Dose)
Table 33. Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Human Granulocyte Colony-stimulating Factor Revenue by Country (2024-2033) & (US$ Million)
Table 35. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region: 2018 VS 2022 VS 2033 (US$ Million)
Table 36. Asia Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2018-2023) & (K Dose)
Table 37. Asia Pacific Human Granulocyte Colony-stimulating Factor Sales by Region (2024-2033) & (K Dose)
Table 38. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue by Region (2024-2033) & (US$ Million)
Table 40. Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country: 2018 VS 2022 VS 2033 (US$ Million)
Table 41. Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (K Dose)
Table 42. Latin America Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2033) & (K Dose)
Table 43. Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Human Granulocyte Colony-stimulating Factor Revenue by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue by Country: 2018 VS 2022 VS 2033 (US$ Million)
Table 46. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2018-2023) & (K Dose)
Table 47. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales by Country (2024-2033) & (K Dose)
Table 48. Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue by Country (2024-2033) & (US$ Million)
Table 50. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Type (2018-2023)
Table 51. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Type (2024-2033)
Table 52. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2018-2023)
Table 53. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Type (2024-2033)
Table 54. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Type (2024-2033)
Table 56. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Type (2018-2023)
Table 57. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Type (2024-2033)
Table 58. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Type (2018-2023)
Table 59. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Type (2024-2033)
Table 60. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Application (2018-2023)
Table 61. Global Human Granulocyte Colony-stimulating Factor Sales (K Dose) by Application (2024-2033)
Table 62. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2018-2023)
Table 63. Global Human Granulocyte Colony-stimulating Factor Sales Market Share by Application (2024-2033)
Table 64. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Human Granulocyte Colony-stimulating Factor Revenue (US$ Million) by Application (2024-2033)
Table 66. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Application (2018-2023)
Table 67. Global Human Granulocyte Colony-stimulating Factor Revenue Market Share by Application (2024-2033)
Table 68. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Application (2018-2023)
Table 69. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Application (2024-2033)
Table 70. Chugai Pharmaceutical Corporation Information
Table 71. Chugai Pharmaceutical Description and Business Overview
Table 72. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 73. Chugai Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
Table 74. Chugai Pharmaceutical Recent Developments/Updates
Table 75. Kyowa Hakko Kirin Corporation Information
Table 76. Kyowa Hakko Kirin Description and Business Overview
Table 77. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 78. Kyowa Hakko Kirin Human Granulocyte Colony-stimulating Factor Product
Table 79. Kyowa Hakko Kirin Recent Developments/Updates
Table 80. Sanway Corporation Information
Table 81. Sanway Description and Business Overview
Table 82. Sanway Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 83. Sanway Human Granulocyte Colony-stimulating Factor Product
Table 84. Sanway Recent Developments/Updates
Table 85. GenSci Corporation Information
Table 86. GenSci Description and Business Overview
Table 87. GenSci Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 88. GenSci Human Granulocyte Colony-stimulating Factor Product
Table 89. GenSci Recent Developments/Updates
Table 90. SL PHARM Corporation Information
Table 91. SL PHARM Description and Business Overview
Table 92. SL PHARM Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 93. SL PHARM Human Granulocyte Colony-stimulating Factor Product
Table 94. SL PHARM Recent Developments/Updates
Table 95. Kexing Bioproducts Corporation Information
Table 96. Kexing Bioproducts Description and Business Overview
Table 97. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 98. Kexing Bioproducts Human Granulocyte Colony-stimulating Factor Product
Table 99. Kexing Bioproducts Recent Developments/Updates
Table 100. Qilu Pharmaceutical Corporation Information
Table 101. Qilu Pharmaceutical Description and Business Overview
Table 102. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 103. Qilu Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
Table 104. Qilu Pharmaceutical Recent Developments/Updates
Table 105. CSPC Corporation Information
Table 106. CSPC Description and Business Overview
Table 107. CSPC Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 108. CSPC Human Granulocyte Colony-stimulating Factor Product
Table 109. CSPC Recent Developments/Updates
Table 110. Wuzhong Pharmaceutical Corporation Information
Table 111. Wuzhong Pharmaceutical Description and Business Overview
Table 112. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 113. Wuzhong Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
Table 114. Wuzhong Pharmaceutical Recent Developments/Updates
Table 115. Quangang Pharmaceutical Corporation Information
Table 116. Quangang Pharmaceutical Description and Business Overview
Table 117. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 118. Quangang Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
Table 119. Quangang Pharmaceutical Recent Developments/Updates
Table 120. Huabei Pharmaceutical Corporation Information
Table 121. Huabei Pharmaceutical Description and Business Overview
Table 122. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 123. Huabei Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
Table 124. Huabei Pharmaceutical Recent Developments/Updates
Table 125. Harbin Pharmaceutical Corporation Information
Table 126. Harbin Pharmaceutical Description and Business Overview
Table 127. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 128. Harbin Pharmaceutical Human Granulocyte Colony-stimulating Factor Product
Table 129. Harbin Pharmaceutical Recent Developments/Updates
Table 130. Amoytop Biotech Corporation Information
Table 131. Amoytop Biotech Description and Business Overview
Table 132. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 133. Amoytop Biotech Human Granulocyte Colony-stimulating Factor Product
Table 134. Amoytop Biotech Recent Developments/Updates
Table 135. Jiuyuan Gene Engineering Corporation Information
Table 136. Jiuyuan Gene Engineering Description and Business Overview
Table 137. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 138. Jiuyuan Gene Engineering Human Granulocyte Colony-stimulating Factor Product
Table 139. Jiuyuan Gene Engineering Recent Developments/Updates
Table 140. Four Rings Biopharmaceutical Corporation Information
Table 141. Four Rings Biopharmaceutical Description and Business Overview
Table 142. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 143. Four Rings Biopharmaceutical Human Granulocyte Colony-stimulating Factor Product
Table 144. Four Rings Biopharmaceutical Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Human Granulocyte Colony-stimulating Factor Distributors List
Table 148. Human Granulocyte Colony-stimulating Factor Customers List
Table 149. Human Granulocyte Colony-stimulating Factor Market Trends
Table 150. Human Granulocyte Colony-stimulating Factor Market Drivers
Table 151. Human Granulocyte Colony-stimulating Factor Market Challenges
Table 152. Human Granulocyte Colony-stimulating Factor Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Human Granulocyte Colony-stimulating Factor
Figure 2. Global Human Granulocyte Colony-stimulating Factor Market Value Comparison by Type (2023-2033) & (US$ Million)
Figure 3. Global Human Granulocyte Colony-stimulating Factor Market Share by Type in 2022 & 2033
Figure 4. 300μg/Dose Product Picture
Figure 5. 150μg/Dose Product Picture
Figure 6. 75μg/Dose Product Picture
Figure 7. Others Product Picture
Figure 8. Global Human Granulocyte Colony-stimulating Factor Market Value Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Human Granulocyte Colony-stimulating Factor Market Share by Application in 2022 & 2033
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Global Human Granulocyte Colony-stimulating Factor Revenue, (US$ Million), 2018 VS 2022 VS 2033
Figure 13. Global Human Granulocyte Colony-stimulating Factor Market Size (2018-2033) & (US$ Million)
Figure 14. Global Human Granulocyte Colony-stimulating Factor Sales (2018-2033) & (K Dose)
Figure 15. Global Human Granulocyte Colony-stimulating Factor Average Price (USD/Dose) & (2018-2033)
Figure 16. Human Granulocyte Colony-stimulating Factor Report Years Considered
Figure 17. Human Granulocyte Colony-stimulating Factor Sales Share by Manufacturers in 2022
Figure 18. Global Human Granulocyte Colony-stimulating Factor Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Human Granulocyte Colony-stimulating Factor Players: Market Share by Revenue in 2022
Figure 20. Human Granulocyte Colony-stimulating Factor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Human Granulocyte Colony-stimulating Factor Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Figure 22. North America Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2018-2033)
Figure 23. North America Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2018-2033)
Figure 24. U.S. Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 25. Canada Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 26. Europe Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2018-2033)
Figure 27. Europe Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2018-2033)
Figure 28. Germany Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 29. France Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 30. U.K. Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 31. Italy Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 32. Russia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 33. Asia Pacific Human Granulocyte Colony-stimulating Factor Sales Market Share by Region (2018-2033)
Figure 34. Asia Pacific Human Granulocyte Colony-stimulating Factor Revenue Market Share by Region (2018-2033)
Figure 35. China Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 36. Japan Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 37. South Korea Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 38. India Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 39. Australia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 40. Taiwan Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 41. Indonesia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 42. Thailand Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 43. Malaysia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 44. Philippines Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 45. Latin America Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2018-2033)
Figure 46. Latin America Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2018-2033)
Figure 47. Mexico Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 48. Brazil Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 49. Argentina Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 50. Middle East & Africa Human Granulocyte Colony-stimulating Factor Sales Market Share by Country (2018-2033)
Figure 51. Middle East & Africa Human Granulocyte Colony-stimulating Factor Revenue Market Share by Country (2018-2033)
Figure 52. Turkey Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 53. Saudi Arabia Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 54. UAE Human Granulocyte Colony-stimulating Factor Revenue Growth Rate (2018-2033) & (US$ Million)
Figure 55. Global Sales Market Share of Human Granulocyte Colony-stimulating Factor by Type (2018-2033)
Figure 56. Global Revenue Market Share of Human Granulocyte Colony-stimulating Factor by Type (2018-2033)
Figure 57. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Type (2018-2033)
Figure 58. Global Sales Market Share of Human Granulocyte Colony-stimulating Factor by Application (2018-2033)
Figure 59. Global Revenue Market Share of Human Granulocyte Colony-stimulating Factor by Application (2018-2033)
Figure 60. Global Human Granulocyte Colony-stimulating Factor Price (USD/Dose) by Application (2018-2033)
Figure 61. Human Granulocyte Colony-stimulating Factor Value Chain
Figure 62. Human Granulocyte Colony-stimulating Factor Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed